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A condition with inadequate oxygen supply to the tissues, hypoxia plays a pivotal role in the pathol-
ogy of cyanotic congenital heart defects and several adult diseases as myocardial infarction, stroke, 
cancer, diabetes, aging, and pulmonary obstruction. Most cell responses to hypoxia are modulated 
by hypoxia-inducible factors [HIFs (1)], DNA-binding transcription factors that mediate hypoxia 
adaptation through activation of a multitude of genes encoding proteins needed to improve tissue 
oxygen delivery, energy metabolism, efficient management of hypoxia-induced stress and regulation 
of apoptosis, autophagy, and cell cycle. The reoxygenation that follows hypoxia usually induces bursts 
of reactive oxygen species, which not only cause the oxidative damage central in the pathophysiol-
ogy of hypoxia/reoxygenation (HReox) injury but also activate signaling mechanisms that in part 
synergize and in part oppose those induced by hypoxia. Consequently, it becomes often difficult 
to distinguish what is attributable to hypoxia and what to the reoxygenation that follows hypoxia. 
A new research frontier may foster clues to understand the mechanisms underlying HReox injury 
and to identify appropriate targets to design interventions aimed at reducing the toll of this injury 
in several diseases.
One example is paradigmatic. For many years, hypoxia was believed to be associated with car-
dioprotection. However, it is now evident that it is not hypoxia, but HReox, the factor providing 
cardioprotection (2), or hypoxic preconditioning (3). In hearts exposed to hypoxia, alterations in 
several signaling paths (4, 5) converge into deleterious phenotypes as right ventricular hypertrophy 
and impaired ability to resist ischemia/reperfusion (6). These findings are corroborated by the clinical 
observation that the outcome of surgery for repair of cyanotic congenital heart defects is complicated 
by myocardial damage due to HReox at the moment of the institution of cardiopulmonary bypass 
with elevated oxygen content, followed by ischemia/reperfusion injury when heart is arrested to 
perform the intra-cardiac repair (7). HReox is related to the intermittent hypoxia (IH) paradigm, 
e.g., repeated exposure to short periods of hypoxia 5–10 times/day. Although displaying protective 
features in the favor of musculoskeletal, pulmonary, central nervous, and cardiopulmonary systems 
(8), IH may have Janus-like features (9): on the one hand, IH is a form of hypoxic preconditioning 
(10); on the other hand, it may become dangerous and pave the road to obstructive sleep apnea 
syndrome (OSAS) (11, 12), which causes harmful redox stress (13).
The purpose of this “Research Topic,” attracting articles dealing with causes and effects of HReox, 
aims at better understanding the underlying pathophysiology and mechanism in the cardiopulmo-
nary system to improve the outcome of clinical management in several classes of pediatric and adult 
patients.
Verges et al. (14) reviewed if and how hypoxic preconditioning is a valid therapeutic modality 
in healthy subjects (hematology, ventilation, cardiovascular system, and metabolic status) and in 
patients affected by cardiovascular (acute myocardial infarction, chronic coronary artery disease, 
heart failure), neurological (stroke, spinal cord injury), respiratory (OSAS, chronic obstructive 
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pulmonary diseases), and metabolic diseases. It appears that 
hypoxic preconditioning, or IH training, is distinguishable from 
dangerous OSAS-like IH essentially for intensity and frequency 
of hypoxia challenges. Indeed, the progression from protective 
to dangerous IH is a continuum based on intensity and physical 
characteristic of the HReox spikes. A role for CO2 handling is 
envisaged because, whereas protective IH is characterized by 
hypocapnic hypoxemia, OSAS-like IH is characterized by hyper-
capnic hypoxemia. In both cases, the molecular determinants for 
the cell response to HReox are primarily HIFs followed by HIF 
downstream responses involving GATA-4, K+ channels, various 
MAPK, EPO, and the PI3K/Akt pathways.
Serebrovskaya and Xi (15) started from the concept that IH 
might occur in early infancy in both preterm and term infants, 
and 2–4% of all children are affected by OSAS. There are numerous 
reports indicating adverse effects of IH on development, behavior, 
achievement, and cognition in OSAS children, although the exact 
causative relationship remains uncertain. On the other hand, 
well-controlled and moderate IH can be used in sick children for 
treating various forms of bronchial asthma, allergic dermatoses, 
autoimmune thyroiditis, cerebral palsy, and obesity. The review 
into the critical role of IH in childhood and comparison of the 
genesis of harmful vs. beneficial effects of IH leads to emphasize 
the dual aspect of IH leading to hypoxia preconditioning and 
OSAS-like IH. Not only CO2 handling but also hypoxia-induced 
polycythemia are identified as most important determinants for 
the divergent effects of these two paradigms.
Hashimoto and Shibasaki (16) clarified the role of HIFs in 
regulating the transcription of genes that mediate the response 
to hypoxia, especially in carcinogenesis and in the pathology of 
ischemic diseases. Unexpectedly, clinical trials targeted at the 
control of therapeutic angiogenesis after the administration of a 
single growth factor have yielded unsatisfactory or controversial 
results for a range of causes accurately examined in their review. 
However, the manipulation of HIF-2α, which plays an essential 
role in vascular remodeling, appears more promising for the 
treatment of ischemic diseases caused by arterial obstruction, 
where insufficient development of collateral vessels impedes 
effective therapy. Indeed, the eukaryotic initiation factor 3 
subunit e (eIF3e)/INT6 has been identified as the molecular 
target that stabilizes specifically HIF-2α even under normoxia, 
thereby inducing the expression of several angiogenic factors, 
and reducing injury in ischemic limbs or cold-injured brains in 
animal models.
Farah and Reboul (17) focused into a most prominent fac-
tor in IH-downstream pathway, e.g., nitric oxide (NO). They 
describe the characteristics of the various NO synthase isoforms 
in providing NO, and the ways by which NO exerts its effects 
against I/R injury, through activation of the guanylate cyclase and 
protein kinase G pathway, or through S-nitrosylation of certain 
proteins. This view of the phenomenon related to the protective 
vs. harmful effects of NO opens a more rational understanding 
of the contribution and importance of NO with respect to the 
subcellular localization (especially with reference to sarcoplasmic 
reticulum and mitochondrial proteins), concentration (NO bio-
availability may be considered advantageous below a threshold 
level but harmful above it), and timing (thus opening an interest-
ing window for oral-based nitrite therapies to prevent I/R injury).
Wellmann et al. (18) described how both hypoxia and hyper-
oxia trigger focal necrosis in brain white matter giving raise to dif-
fuse white matter diseases, and consequently disturb myelination 
in newborn infants during a critical developmental window prior 
to the onset of myelination. This may represent the underlying 
cause for an array of cognitive and behavioral diseases. Using 
various targeted experimental models, it has been shown that the 
molecular basis of such phenotypes, e.g., HIF-1α and HIF-2α, can 
be activated by both hypoxia (through the canonical β-catenin-
Wnt signaling) and paradoxically by a situation that resembles 
hyperoxia (transgenic embryonic mice unable to express HIF-1α 
and HIF-2α). Such findings emphasize the importance of avoid-
ing extremes of oxygen tension in the brains of preterm infants 
and in infants with congenital heart disease undergoing surgery.
In summary, these reviews converge into the view that appro-
priate management of HReox may help curing many diseases and 
may provide pediatric surgeons valuable tools to reduce hypoxia-
induced complicacies (2, 19).
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